LBX(SH:603883) Sou Hu Cai Jing·2025-08-07 15:18Group 1 - The core idea of the new centralized drug procurement policy emphasizes "no procurement for new drugs, and new drugs are not included in procurement" to protect industry innovation and ensure reasonable returns for innovative drugs during their initial market period [1][2] - The new procurement rules will not use the lowest price as a reference, which aims to avoid the elimination of normal-priced companies and is expected to increase the average price level of selected drugs [2] - The procurement process respects clinical needs by allowing pharmacies to participate, thus broadening the sales channels for procured drugs and enhancing accessibility for patients [3] Group 2 - The selection of drugs for procurement focuses on those with procurement amounts exceeding 100 million yuan in 2024, allowing companies more time to develop and cultivate the market [1] - A mechanism has been introduced to allow non-selected companies to "revive" their bids by lowering prices, promoting rational competition among enterprises [2] - Special consideration has been given to children's medications by creating an independent grouping, which aims to improve the accessibility of these essential drugs [3]